Infinimmune and Merck (MRK) Enter into an Antibody Discovery Agreement

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Performing Dow Stocks So Far in 2026.

On March 31, 2026, Reuters announced that Infinimmune has signed an agreement with Merck & Co., Inc. (NYSE:MRK) to research and develop several antibody candidates, with potential milestone payments totaling $838 million. The deal includes an undisclosed upfront payment to Infinimmune. Merck & Co., Inc. (NYSE:MRK) retains exclusive rights to develop and commercialize the ensuing medicines.

Infinimmune announced that it will use its exclusive technology to screen vast volumes of human immune cells. It is discovering naturally existing antibodies and improving them with artificial intelligence methods. CEO of Infinimmune Wyatt McDonnell told Reuters that the technology promotes antibodies that have already been sculpted by human biology rather than creating them from scratch.

The firms will investigate various secret targets chosen by Merck & Co., Inc. (NYSE:MRK). McDonnell stressed that the relationship is not limited to a specific disease area. Infinimmune is also exploring internal early-stage treatments for moderate-to-severe eczema and other immune-related disorders.

Infinimmune and Merck (MRK) Enter into an Antibody Discovery Agreement

Merck & Co., Inc. (NYSE:MRK) is a healthcare firm that provides health solutions through prescription medications, vaccines, biologic therapies, animal health, and consumer care products. It operates in three segments: pharmaceutical, animal health, and other.

While we acknowledge the risk and potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.